9 September 2021 - Senate lawmakers are actively considering pegging the prices Medicare pays for drugs to those drug makers offer to other government programs like the nation’s veterans health program, according to sources familiar with the discussions as well as an internal slide deck obtained by STAT.
The proposal, known internally as domestic reference pricing, could have a multibillion-dollar impact on drug makers, which have long opposed allowing Medicare to negotiate over drug prices.